Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study

With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.

Gilead HQ
Gilead increases its investment in Arcus and the anti-TIGIT mechanism • Source: Shutterstock

The latest event in the nearly four-year collaboration between Gilead Sciences, Inc. and Arcus Biosciences, Inc. saw Gilead increase its equity stake in its partner to approximately 33% in a transaction that Arcus said would give it financial runway into 2027. The two companies also announced that they are ending enrollment in a chemotherapy-free lung cancer trial to focus on other Phase III studies, while Arcus said it will conduct Phase III development of CD73 inhibitor quemliclustat in pancreatic cancer on its own.

Key Takeaways
  • Gilead increases its stake in Arcus, by paying $320m at a 37% premium to reach 33% equity in its partner.

Gilead announced after market close on 29 January that it will make a $320m equity investment in Arcus, increasing its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

More from Business

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.